Company profile: Ratio Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-phase radiopharmaceuticals for solid tumors, with the Trillium platform for pharmacokinetic modulation to improve tumor-targeted delivery, the Macropa chelator for actinium-225 conjugation, FAP-targeted therapies including a PET diagnostic, and a Granzyme B PET imaging agent to monitor immune response in cancer and inflammatory diseases.
Products and services
- FAP-targeted Radiopharmaceuticals: Develops PET-based, tumor-directed products targeting fibroblast activation protein in solid tumors, including a PET diagnostic compound for tumor imaging
- Trillium: Architects a platform-based technology for pharmacokinetic modulation that optimizes drug delivery and efficacy in tumor targeting
- Macropa: Proprietary, actinium-225 chelator that attaches to compounds, enhancing in vivo stability and easing manufacturing for radiopharmaceutical development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ratio Therapeutics
Phoenix Biotechnology
HQ: United States
Website
- Description: Provider of research and development of therapeutic agents and treatment regimens for cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phoenix Biotechnology company profile →
Pulse Biosciences
HQ: United States
Website
- Description: Provider of medical devices using Nanosecond Pulsed Field Ablation (nsPFA), including the CellFX System for various therapeutic areas including cardiology; the CellFX nsPFA 360 Cardiac Catheter for atrial fibrillation pulmonary vein isolation; the CellFX nsPFA Cardiac Clamp for surgical cardiac ablation; and a percutaneous electrode for non-cardiac, nonthermal ablation of cellular tissue while sparing noncellular structures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pulse Biosciences company profile →
Boundless Bio
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and diagnostics targeting extrachromosomal DNA (ecDNA) in aggressive cancers, including BBI-355 (oral CHK1 inhibitor for ecDNA-enabled oncogene amplified cells), BBI-825 (oral RNR inhibitor disrupting ecDNA assembly and repair), the Spyglass platform to identify and validate druggable targets in ecDNA-cancer cells, and ECHO to detect ecDNA from routine clinical next-generation sequencing data.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boundless Bio company profile →
Mobidiag
HQ: Finland
Website
- Description: Provider of molecular diagnostic solutions for the detection of infectious diseases, including gastrointestinal infections, antimicrobial resistance management, healthcare-associated infections (HAIs), respiratory infections and sepsis, based on well-established qPCR and microarray technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mobidiag company profile →
Amcure
HQ: Germany
Website
- Description: Provider of peptide-based compounds in clinical development for the treatment of highly metastatic forms of squamous cancer; a privately held spin-off from the Karlsruhe Institute of Technology established in 2012 and supported by a grant from the German Federal Ministry of Education and Research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Amcure company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ratio Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ratio Therapeutics
2.2 - Growth funds investing in similar companies to Ratio Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ratio Therapeutics
4.2 - Public trading comparable groups for Ratio Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →